financetom
Business
financetom
/
Business
/
Australia regulator accepts ANZ's undertaking to fix risk culture; hikes capital add-on
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Australia regulator accepts ANZ's undertaking to fix risk culture; hikes capital add-on
Apr 2, 2025 2:24 PM

(Reuters) - Australia's prudential watchdog said on Thursday it had accepted a court-enforceable undertaking from ANZ Group ( ANZGF ) to address the lender's non-financial risk management practices and risk culture.

The Australian Prudential Regulation Authority (APRA) also raised the amount of spare cash that the country's No. 4 lender must keep on hand to A$1 billion ($628.50 million) from A$750 million.

In August, the regulator had asked ANZ to conduct an independent review program to determine root causes of its issues.

"APRA has assessed that the completion of this program alone will not effectively and sustainably address the broader non-financial risk weaknesses across ANZ," it said.

ANZ said in a separate statement that it had accepted all recommendations of the review, and was taking immediate actions in response to the review and the undertaking with APRA.

"We are disappointed that we have not met APRA's expectations about how the bank manages non-financial risk and its non-financial risk culture," ANZ Chairman Paul O'Sullivan said.

($1 = 1.5911 Australian dollars)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Addex Therapeutics Says Partner J&J Innovative Medicine Discontinues Development of ADX71149 to Treat Epilepsy; Addex Shares Fall Pre-Bell
Addex Therapeutics Says Partner J&J Innovative Medicine Discontinues Development of ADX71149 to Treat Epilepsy; Addex Shares Fall Pre-Bell
Jul 22, 2024
09:31 AM EDT, 07/22/2024 (MT Newswires) -- Addex Therapeutics ( ADXN ) said Monday its partner J&J Innovative Medicine, formerly Janssen Pharmaceuticals, has said it has discontinued development of ADX71149 to treat epilepsy. Addex said top-line phase 2 trial results disclosed on April 29 showed that administration of ADX71149 in people with focal onset seizures with suboptimal response to levetiracetam...
Market Chatter: McDonald's to Extend $5 Meal Deal, Explore Longer Operating Hours
Market Chatter: McDonald's to Extend $5 Meal Deal, Explore Longer Operating Hours
Jul 22, 2024
09:32 AM EDT, 07/22/2024 (MT Newswires) -- McDonald's (MCD) will extend its $5 meal deal at nearly 93% of its US locations beyond the initial four-week period, with some continuing through August, Bloomberg reported Monday, citing a company memo. Early results suggest the deal is meeting the objective of driving guests back to our restaurants, Bloomberg quoted McDonald's Chief Marketing...
Reddit partners with NFL, NBA to boost revenue
Reddit partners with NFL, NBA to boost revenue
Jul 22, 2024
July 22 (Reuters) - Reddit ( RDDT ) has struck deals with sports leagues, including the National Basketball Association and the National Football League, in an attempt to boost revenue, the social media platform said on Monday. ...
BWX Technologies Unit BWXT Medical and NorthStar Collaborating to Produce Cancer-Fighting Isotope
BWX Technologies Unit BWXT Medical and NorthStar Collaborating to Produce Cancer-Fighting Isotope
Jul 22, 2024
09:28 AM EDT, 07/22/2024 (MT Newswires) -- BWX Technologies ( BWXT ) subsidiary BWXT Medical and NorthStar Medical Radioisotopes said Monday they signed a master services agreement to produce actinium-225, a medical isotope for cancer treatment. Under the multi-year agreement, the companies will collaborate to process and purify radium-226 to generate actinium-225, with potential projects for target design and backup...
Copyright 2023-2025 - www.financetom.com All Rights Reserved